ZEISS Expands its OCT Portfolio with an Imaging Solution Ideal for Small Eye Care Practices

The new PRIMUS 200 empowers small practices to offer their patients more comprehensive eye care, with a compact, easy-to-use OCT system that provides essential applications for retina, glaucoma and anterior segment.


PRIMUS 200 is a versatile optical coherence tomography (OCT) system designed to help eye care providers expand their practices and raise their level of clinical care. As OCT is the standard of care for many types of eye diseases, PRIMUS, with key applications for the posterior and anterior segment of the eye, enables practices to broaden their in-house services to a greater range of patients.  

PRIMUS 200 offers advanced technology and the high level of quality expected from ZEISS, the company that pioneered OCT more than 20 years ago and the manufacturer of the market-leading CIRRUS™ HD-OCT. The smaller footprint, simple design and short learning curve of PRIMUS 200 make it easy to integrate into smaller eye care practices. In addition:  

  • Brilliant image quality, proven ZEISS algorithms and an onboard pathology library help eye care providers make more confident and informed clinical decisions.
  • Auto-fovea finder and Auto-Center features support reliable, operator-independent results, which increases clinical confidence.
    Minimal chin time and no dilation down to 2mm pupils enhance patient comfort.
  • System-guided navigation and report-driven workflow make the system easy to learn and use.

“It took less than 10 to 15 minutes for my entire team to learn how to use the PRIMUS 200. Optometrists on my team with no prior OCT experience picked up on this device quite easily,” said Dr. Bhargava Natesh of Nethra Eye Hospital in Bangalore, India. “Image acquisition and processing were also very fast. It can help us go from one patient to another quickly.”

OCT is the standard of care for retina and glaucoma diagnostics, and in addition doctors treating cataracts use OCT for pre-operative assessment. Checking the overall health of the retina prior to cataract surgery helps cataract surgeons plan for the best treatment option, optimize outcomes and avoid surprises post-surgery.

“At ZEISS, we believe that all eye care practices, regardless of size or specialty, should have access to advanced technologies that will help them deliver the best possible care for their patients,” said Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. “Our offering is especially dedicated to customers who want to grow their practice. PRIMUS 200 not only enhances quality of care in these practice settings, but also it helps these smaller practices offer their patients more comprehensive eye care.”

PRIMUS 200 is CE marked and is available for order in many countries in Europe. The device is not approved for sale in the United States. Attendees of the 2015 European Society of Cataract and Refractive Surgeons Annual Meeting are invited to visit ZEISS booth F05 for a first-hand demonstration of the system.

Brief profile

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumable materials. The Company creates innovative visualization solutions in the field of microsurgery. The medical technology portfolio of Carl Zeiss Meditec is rounded off by promising, future-oriented technologies such as intraoperative radiotherapy. With almost 3,000 employees, the Group generated revenue of € 909 million in financial year 2013/2014 (to 30 September).

The head office of Carl Zeiss Meditec is in Jena, Germany. The Company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Research and Development (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec shares are in free float. The remaining approx. 65 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.
Carl Zeiss offers innovative solutions for the future-oriented markets Industrial Solutions, Research Solutions, Medical Technology and Consumer Optics. Carl Zeiss AG, Oberkochen, is wholly owned by the Carl Zeiss Foundation.

For more information visit our website at: